MYGN — Myriad Genetics Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Myriad Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 June 30th	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	639	691	678	753	838
Cost of Revenue
Gross Profit	453	493	476	517	585
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	869	741	819	1,011	959
Operating Profit	-231	-50	-141	-257	-121
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-223	-57.1	-141	-262	-124
Provision for Income Taxes
Net Income After Taxes	-200	-24.5	-112	-263	-127
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-200	-27.2	-112	-263	-127
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-200	-27.2	-112	-263	-127
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.82	-0.948	-1.25	-2.23	-1.17